Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Biometrical Journal. Biometrische Zeitschrift
|
October 28, 2025
Variable Selection via Fused Sparse-Group Lasso Penalized Multi-state Models Incorporating Molecular Data
Kaya Miah, Jelle J Goeman, Hein Putter, et al.
Cells
|
August 12, 2022
Assessment of a Serum Microrna Risk Score for Colorectal Cancer among Participants of Screening Colonoscopy at Various Stages of Colorectal Carcinogenesis
Janhavi R Raut, Megha Bhardwaj, Tobias Niedermaier, et al.
Nature Communications
|
August 11, 2021
A microRNA panel compared to environmental and polygenic scores for colorectal cancer risk prediction
Janhavi R Raut, Ben Schöttker, Bernd Holleczek, et al.
Oncology
|
October 3, 2024
Efficacy and Safety of Autologous Stem Cell Transplantation in First-Line Treatment and at Relapse in Elderly Patients with Multiple Myeloma
Eva-Maria Klein, Sejla Hujic, Kaya Miah, et al.
Frontiers in Oncology
|
May 8, 2023
Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma
Lukas John, Kaya Miah, Axel Benner, et al.
Blood Cancer Journal
|
January 4, 2023
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
Elias K Mai, Stefanie Huhn, Kaya Miah, et al.
European Journal of Haematology
|
November 11, 2025
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial
Tim Richardson, Elias Mai, Ekaterina Menis, et al.
Blood
|
January 6, 2023
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma
Nicola Giesen, Manik Chatterjee, Christof Scheid, et al.
Leukemia
|
May 25, 2021
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial
Hans Salwender, Ahmet Elmaagacli, Maximilian Merz, et al.
Hematology (Amsterdam, Netherlands)
|
February 26, 2024
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial
Hans Salwender, Niels Weinhold, Axel Benner, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Biometrical Journal. Biometrische Zeitschrift
|
October 28, 2025
Variable Selection via Fused Sparse-Group Lasso Penalized Multi-state Models Incorporating Molecular Data
Kaya Miah, Jelle J Goeman, Hein Putter, et al.
Cells
|
August 12, 2022
Assessment of a Serum Microrna Risk Score for Colorectal Cancer among Participants of Screening Colonoscopy at Various Stages of Colorectal Carcinogenesis
Janhavi R Raut, Megha Bhardwaj, Tobias Niedermaier, et al.
Nature Communications
|
August 11, 2021
A microRNA panel compared to environmental and polygenic scores for colorectal cancer risk prediction
Janhavi R Raut, Ben Schöttker, Bernd Holleczek, et al.
Oncology
|
October 3, 2024
Efficacy and Safety of Autologous Stem Cell Transplantation in First-Line Treatment and at Relapse in Elderly Patients with Multiple Myeloma
Eva-Maria Klein, Sejla Hujic, Kaya Miah, et al.
Frontiers in Oncology
|
May 8, 2023
Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma
Lukas John, Kaya Miah, Axel Benner, et al.
Blood Cancer Journal
|
January 4, 2023
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
Elias K Mai, Stefanie Huhn, Kaya Miah, et al.
European Journal of Haematology
|
November 11, 2025
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial
Tim Richardson, Elias Mai, Ekaterina Menis, et al.
Blood
|
January 6, 2023
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma
Nicola Giesen, Manik Chatterjee, Christof Scheid, et al.
Leukemia
|
May 25, 2021
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial
Hans Salwender, Ahmet Elmaagacli, Maximilian Merz, et al.
Hematology (Amsterdam, Netherlands)
|
February 26, 2024
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial
Hans Salwender, Niels Weinhold, Axel Benner, et al.
Page
of 2